key: cord-1045595-zwsvlnwe
authors: Felipe, Lorena Sanchez; Vercruysse, Thomas; Sharma, Sapna; Ma, Ji; Lemmens, Viktor; van Looveren, Dominique; Arkalagud Javarappa, Mahadesh Prasad; Boudewijns, Robbert; Malengier-Devlies, Bert; Kaptein, Suzanne F.; Liesenborghs, Laurens; De Keyzer, Carolien; Bervoets, Lindsey; Rasulova, Madina; Seldeslachts, Laura; Jansen, Sander; Yakass, Michael Bright; Quaye, Osbourne; Li, Li-Hsin; Zhang, Xin; Horst, Sebastiaan ter; Mishra, Niraj; Coelmont, Lotte; Cawthorne, Christopher; Van Laere, Koen; Opdenakker, Ghislain; Van de Velde, Greetje; Weynand, Birgit; Teuwen, Dirk E.; Matthys, Patrick; Neyts, Johan; Thibaut, Hendrik Jan; Dallmeier, Kai
title: A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate
date: 2020-07-09
journal: bioRxiv
DOI: 10.1101/2020.07.08.193045
sha: c9e57424da6d47c0eaf792970a54a9d576bb5fe5
doc_id: 1045595
cord_uid: zwsvlnwe

The explosively expanding COVID-19 pandemic urges the development of safe, efficacious and fast-acting vaccines to quench the unrestrained spread of SARS-CoV-2. Several promising vaccine platforms, developed in recent years, are leveraged for a rapid emergency response to COVID-191. We employed the live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express the prefusion form of the SARS-CoV-2 Spike antigen. In mice, the vaccine candidate, tentatively named YF-S0, induces high levels of SARS-CoV-2 neutralizing antibodies and a favorable Th1 cell-mediated immune response. In a stringent hamster SARS-CoV-2 challenge model2, vaccine candidate YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose confers protection from lung disease in most vaccinated animals even within 10 days. These results warrant further development of YF-S0 as a potent SARS-CoV-2 vaccine candidate.

strain (GenBank: MN908947.3), as in-frame fusion within the YF17D-E/NS1 intergenic region 71 (YF-S1/2, YF-S0 and YF-S1) ( Figure 1A , Figure S1 ). As outlined below, variant YF-S0 was 72 finally selected as lead vaccine candidate based on its superior immunogenicity, efficacy and 73 favorable safety profile. with YF-S0 only half needed to be euthanized (MDE 17,5 days). For the YF-S1/2 and YF-S1 91 groups MDE was 12 and 10 days respectively; thus in particular YF-S0 has a markedly reduced 92 neurovirulence. Likewise, YF-S0 is also highly attenuated in type I and II interferon receptor 93 deficient AG129 mice, that are highly susceptible to (a neurotropic) YF17D infection 13, 14 . 94 Whereas 1 PFU of YF17D resulted in neuro-invasion requiring euthanasia of all mice (MDE 95 16 days) ( Figure 2B ), a 1000-fold higher inoculum of YF-S0 did not result in any disease 96 ( Figure S2C ) and only 1 in 12 animals that received a 10,000 higher inoculum needed to be 97 euthanized ( Figure 2B ). In summary, a set of transgenic replication-competent YF17D variants 98 (YF-S) was generated that express different forms of the SARS-CoV-2 S antigen and that are 99 highly attenuated in mice in terms of neurovirulence and neurotropism as compared to YF17D. Figure S3 for benchmarking of SARS-CoV-2 serum neutralization test, 109 SNT). For YF-S1/2 log10 geometric mean titers (GMT) for IgG and nAbs were 3.2 (95% CI, 110 2.9-3.5) and 1.4 (95% CI, 1.1-1.9) respectively, while in the case of YF-S0 GMT values for 111 IgG and nAbs of 3.5 (95% CI, 3.3-3.8) and 2.2 (95% CI, 1.9-2.6) were measured, with rapid 112 seroconversion kinetics (50% seroconversion rate < 2 weeks; Figure 3D ). By contrast, only 1 113 out of 12 hamsters that had received YF-S1 seroconverted and this with a low level of nAbs. Figure 3D ), and of 5.3 log10 (IQR, 3.9-6.3) for infectious SARS-CoV-2 virus in the 126 lungs (p <0.0001; Figure 3E ). Moreover, infectious virus was no longer detectable in 10 of 12 127 hamsters (two independent experiments), and viral RNA was reduced to non-quantifiable levels 128 in their lungs. Residual RNA measured in 2 out of 12 animals may equally well represent 129 residues of the high-titer inoculum as observed in non-human primate models 15-18 . Vaccination 130 with YF-S0 (two doses of 10 3 PFU) also efficiently prevented systemic viral dissemination; in 131 most animals, no or only very low levels of viral RNA were detectable in spleen, liver, kidney 132 and heart four days after infection ( Figure S4A ). Similarly and in full support, a slightly 133 different dose and schedule used for vaccination (5 x 10 3 PFU of YF-S0 at day 0 and 7 134 respectively) resulted in all vaccinated hamsters (n=7) in respectively a 6 log10 (IQR, 4.6-6.6) 135 and 5.7 log10 (IQR, 5.7-6.6) reduction of viral RNA and infectious virus titers as compared to 136 sham ( Figure S5 ). Finally, vaccination with YF-S0 may induce saturating levels of nAbs 137 thereby conferring sterilizing immunity, as demonstrated by the fact that in about half of the 138 YF-S0 vaccinated hamsters no anamnestic antibody response was observed following challenge 139 ( Figure 3G and S4B-D (paired nAb analysis)). By contrast, in hamsters vaccinated with the 140 second-best vaccine candidate YF-S1/2, nAb levels further increased following SARS-CoV-2 141 infection (in 11 out of 12 animals) whereby a plateau was only approached after challenge.

The lungs of YF-S0 vaccinated animals remained normal, or near to normal with no more signs 143 of bronchopneumonia which is markedly different to sham-vaccinated animals (n=12 from two 144 independent experiments; Figure 4 ). The specific disease scores and biomarkers quantified 2 145 included (i) a reduction or lack of detectable lung pathology as observed by histological 146 inspection ( Figure 4A ,B, Figure S6A) ; and, (ii) a significant improvement of the individual lung 147 scores (p = 0.002) ( Figure 4C , Figure S6B ) and respiratory capacity (i.e* 32% less of lung 148 volume obstructed; p = 0.0323; Figure 4D ) in YF-S0 vaccinated animals as derived by micro- Figure 4F and Figure S7 ).

Overall, YF-S0 that expresses the non-cleavable S variant outcompeted construct YF-S1/2 157 expressing the cleavable version of S. This argues for the stabilized prefusion form of S serving 158 as a relevant protective antigen for SARS-CoV-2. Moreover, in line with its failure to induce 159 nAbs ( Figure 3B ), construct YF-S1 expressing solely the hACE2 receptor-binding S1 domain Since there are very few tools available to study CMI in hamsters, humoral and CMI responses 166 elicited by the different YF-S constructs were studied in parallel in mice. Since YF17D does 167 not readily replicate in wild-type mice 23,24 , Ifnar -/mice that are deficient in Type I interferon 168 signaling and that are hence susceptible to vaccination with YF17D, were employed 10,24,25 .

Mice were vaccinated with 400 PFU (of either of the YF-S variants, YF17D or sham) at day 0 170 and were boosted with the same dose 7 days later ( Figure 5A ). At day 21 all YF-S1/2 and YF-171 S0 vaccinated mice (n>9 in three independent experiments) had seroconverted to high levels of 172 S-specific IgG and nAbs with log10 GMT of 3.5 (95% CI, 3.1-3.9 ) for IgG and 2.2 (95% CI, 173 1.7-2.7) for nAbs in the case of YF-S1/2, or 4.0 (95% CI, 3.7-4.2) for IgG and 3.0 (95% CI, 174 2.8-3.1) for nAbs in the case of YF-S0 ( Figure 5B ,C). Importantly, seroconversion to S-specific 175 IgG was detectable as early as 7 days after the first immunization ( Figure 5D ). Isotyping of IgG induced by all constructs confirming a consistent immunization ( Figure S8 ).

To assess SARS-CoV-2-specific CMI responses that play a pivotal role for the shaping and Figure 7E ). It should be noted that viral RNA at quantifiable levels was present in only 223 1 out of 8 animals ( Figure 7D ). In addition, protective immunity was mounted rapidly. Already Vaccines against SARS-CoV-2 need to be safe and result rapidly, ideally after one single dose, 229 in long-lasting protective immunity. Different SARS-CoV-2 vaccine candidates are being 230 developed, and several are vector-based. We report encouraging results of YF17D-vectored 231 SARS-CoV-2 vaccine candidates. The post-fusion (S1/2), pre-fusion (S0) as well as the RBD 232 S1 domain (S1) of the SARS-CoV-2 Spike protein were inserted in the YF17D backbone to 233 yield the YF-S1/2, YF-S0 and YF-S1, respectively ( Figure S1 ). The YF-S0 vaccine candidate, 234 in particular, resulted in a robust humoral immune response in both, mice and Syrian hamsters. Moreover, YF-S0 showed in two mice models a favorable safety profile as compared to the 250 parental YF17D vector (Figure 2A and B) . This is of importance as YF17D vaccine is contra-251 indicated in elderly and persons with underlying medical conditions. These preliminary, though 252 encouraging, data suggest that YF-S0 might also be safe in those persons most vulnerable to 253 COVID-19. 254 In addition, cell-mediated immunity (CMI) studied in mice revealed that YF-S0, besides was observed in our models.

In conclusion, YF-S0 confers vigorous protective immunity against SARS-CoV-2 infection.

Remarkably, this immunity can be achieved within 10 days following a single dose vaccination.

In light of the threat SARS-CoV-2 will remain endemic with spikes of re-infection, as a 267 recurring plague, vaccines with this profile may be ideally suited for population-wide 268 immunization programs. Figure S1 ). The variants generated 290 contained (i) either the S protein sequence from amino acid (aa) 14-1273, expressing S in its 291 post-fusion and/or prefusion conformation (YF-S1/2 and YF-S0, respectively), or (ii) its 292 subunit-S1 (aa 14-722; YF-S1). To ensure a proper YF topology and correct expression of ELISpot, transcription factor analysis by qPCR and intracellular cytokine staining (ICS).

The presence of infectious SARS-CoV-2 particles in lung homogenates was quantified by days) after intracranial (i.c.) inoculation with 100 PFU of vaccine candidates YF-S1/2 (n=8, blue), YF-726 S0 (n=8, green), YF-S1 (n=8, red) in comparison to sham (n=10, grey) or YF17D (n=9, black). (B) 727

Survival curve of AG129 mice (up to 21 days) after intraperitoneal (i.p.) inoculation with a dose range 728

of YF-S0 (10 2 , 10 3 and 10 4 PFU; green) in comparison to YF17D (1, 10 and 10 2 PFU black and grey). 729

Statistical significance between groups was calculated by the Log-rank Mantel-Cox test (**** P < 730 0.0001). 731

Statistical significance between conditions was calculated by the non-parametric ANOVA, Kruskall-778

Wallis with uncorrected Dunn's test (ns = Not-Significant, P > 0.05, * P < 0.05, ** P < 0.01, *** P < 779 0.001). 400 PFU each at day 0 and 7 in five groups: constructs YF-S1/2 (blue, n=11), YF-S0 (green, n=11), YF-785 S1 (red, n=13), sham (white, n=9) or YF17D (grey, n=9). (B, C) SARS-CoV-2 specific antibody levels.

Titers of nAbs (B) and bAbs (C) at day 21 post-vaccination. (D) Seroconversion rates. Rates at 787

indicated days post-vaccination with YF-S1/2 and YF-S0 (number of animals with detectable bAbs at 788 each time point are referenced). For quantification of bAbs, minipools of sera of two to three animals 789 each were analyzed. Dotted lines indicate lower limit of quantification (LLOQ) or lower limit of 790 detection (LLOD). (E) IgG for YF-S1/2 (blue) and YF-S0 (green). Ratios of IgG2b or IgG2c over 791 IgG1 (determined for minipools of two to three animals each) plotted and compared to a theoretical limit 792 between Th1 and Th2 response (dotted line indicates IgG2b/c over IgG1 ratio of 1). Data shown are 793 medians ± IQR from three independent vaccination experiments (n > 9 for each condition). Statistical 794 significance between groups was calculated by a non-parametric ANOVA, Kruskall-Wallis with 795

uncorrected Dunn's test (B-C) or parametric One-Sample T-test (D) (ns = Not-Significant, P > 0.05, * P 796 < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). 797 798 799

STAT2 signaling as double-edged sword restricting viral dissemination 566 but driving severe pneumonia in SARS-CoV-2 infected hamsters. bioRxiv

Importance of Neutralizing Monoclonal Antibodies Targeting Multiple 569

Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To 570 Avoid Neutralization Escape

Contributions of the structural proteins of severe acute respiratory 572 syndrome coronavirus to protective immunity

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-575 Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-578 Domain Camelid Antibodies

Systems biology approach predicts immunogenicity of the yellow fever 581 vaccine in humans

Yellow fever vaccine -how does it work and why do rare cases 583 of serious adverse events take place?

Viruses as vaccine vectors for infectious diseases and cancer

A yellow fever-Zika chimeric virus vaccine candidate protects against Zika 588 infection and congenital malformations in mice

The yellow fever 17D virus as a platform for new 591 live attenuated vaccines

Simple and inexpensive three-step rapid amplification of cDNA 5' 594 ends using 5' phosphorylated primers

Limited evolution of the yellow fever virus 17d in a mouse infection model

A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow 599 Fever Virus Infection without Inducing Neutralizing Antibodies

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman 602 primate model

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in 604 rhesus macaques. bioRxiv

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-608 coronavirus 2

A Novel Coronavirus from Patients with Pneumonia in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of 138 Hospitalized Patients With

COVID-19 and emerging viral infections: The case for interferon 617 lambda

Mouse 619 Model for Studying Viscerotropic Disease Caused by Yellow Fever Virus Infection

Dynamic Viral Dissemination in Mice Infected with Yellow Fever 622

The 17D-204 Vaccine Strain-Induced 624 Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ 625 but not CD8+ T Cells

Dysregulated Type I Interferon and Inflammatory Monocyte-627

Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

Pathogenic human coronavirus infections: causes and 630 consequences of cytokine storm and immunopathology

Induction of alternatively activated macrophages enhances pathogenesis 633 during severe acute respiratory syndrome coronavirus infection

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with 636 COVID-19 Disease and Unexposed Individuals

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity

Simulation of the clinical and pathological manifestations of Coronavirus 642 Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease 643 pathogenesis and transmissibility

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Syrian hamsters as a small animal model for SARS-CoV-2 infection and 648 countermeasure development

Development of an inactivated vaccine candidate for SARS-CoV-2

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses 653 during acute SARS-CoV infection

Viral-Induced Enhanced Disease Illness. Front 655 Microbiol 9

Trans-Complementation of yellow fever virus NS1 reveals a role 657 in early RNA replication

Generation of bovine respiratory syncytial virus 660 (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the 661 human RSV leader region acts as a functional BRSV genome promoter

Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-664 launched live-attenuated yellow fever vaccine

A recombinant Yellow Fever 17D vaccine expressing Lassa virus 667 glycoproteins

Functional role of type I and type II interferons in antiviral defense

Immune defence 671 in mice lacking type I and/or type II interferon receptors

Analysis of relative gene expression data using real-time 674 quantitative PCR and the 2(-Delta Delta C(T)) Method

Iterative CT Reconstruction Using Shearlet-Based Regularization. 680 Nuclear Science

Longitudinal micro-CT provides biomarkers of lung disease that can be 682 used to assess the effect of therapy in preclinical mouse models, and reveal compensatory 683 changes in lung volume

Radiosafe micro-computed tomography for longitudinal evaluation of 685 murine disease models

Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect 687 of favipiravir and a complete lack of effect for hydroxychloroquine. bioRxiv

In vivo blunt-end 690 cloning through CRISPR/Cas9-facilitated non-homologous end-joining

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus 693 entry, identification of entry inhibitors, and immune responses to vaccines

A vesicular stomatitis virus replicon-based bioassay for the 696 rapid and sensitive determination of multi-species type I interferon

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by 699 a Clinically Proven Protease Inhibitor

Vesicular stomatitis virus pseudotyped with severe acute respiratory 702 syndrome coronavirus spike protein

Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 705 infection

Mutations in the Spike Protein of Middle East Respiratory Syndrome 707

Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization

YF-S1/2 expresses the native cleavable post-fusion form of the S protein 712 (S1/2), YF-S0 the non-cleavable pre-fusion conformation (S0), and YF-S1 the N-terminal (receptor 713 binding domain) containing S1 subunit of the S protein. For molecular details in vaccine design see 714 Methods section. (B) Representative pictures of plaque phenotypes from different YF-S vaccine 715 constructs on BHK-21 cells in comparison to YF17D. (C) Confocal immunofluorescent images of BHK-716 21 cells three days post-infection

Spike antigen (green) and YF17D (red) (nuclei stained with DAPI, blue; white scalebar: 25 µm)

Immunoblot analysis of SARS-CoV-2 Spike (S1/2, S0 and S1) antigen and SARS Spike expression after 719 transduction of BHK-21 cells with different YF-S vaccine candidates

Immunogenicity and protective efficacy of YF-S vaccine candidates in hamsters

Syrian hamsters were immunized 735 twice i.p. at day 0 and 7 with 10 3 PFU each of vaccine constructs YF-S1/2 (blue, n=12), YF-S0 (green

Viral RNA levels were determined in the lungs, 745 normalized against β-actin and fold-changes were calculated using the 2 (-ΔΔCq) method compared to the 746 median of sham-vaccinated hamsters. Infectious viral loads in the lungs are expressed as number of 747 infectious virus particles per 100 mg of lung tissue. (G) Anamnestic response. Comparison of the levels 748 of nAbs prior and four days after challenge. For a pairwise comparison of responses in individual 749 animals see Supplementary Figure S4C and D. Dotted line indicating lower limit of quantification 750 (LLOQ) or lower limit of detection (LLOD) as indicated. Data shown are medians ± IQR. Statistical 751 significance between groups was calculated by the non-parametric ANOVA, Kruskall-Wallis with 752 uncorrected Dunn's test (B-F), or a non-parametric two-tailed Wilcoxon matched-pairs rank test (G) (ns 753 = Non-Significant

Representative H&E images 759 of the lungs of a diseased (sham-vaccinated and infected) and a YF-S0-vaccinated and challenged 760 hamster. Peri-vascular edema (blue arrow); peri-bronchial inflammation (red arrows); peri-vascular 761 inflammation (green arrow); bronchopneumonia (circle), apoptotic body in bronchial wall (red 762 arrowhead). (B) A spider-web plot showing histopathological score for signs of lung damage (peri-763 vascular edema, bronchopneumonia, peri-vascular inflammation, peri-bronchial inflammation

Five transverse cross 766 sections at different positions in the lung were selected for each animal and scored to quantify lung 767 consolidations (C) or used to quantify the non-aerated lung volume (NALV) (D), as functional 768 biomarker reflecting lung consolidation. (E) Heat-map showing differential expression of selected 769 antiviral, pro-inflammatory and cytokine genes in lungs of sham-or YF-S-vaccinated hamsters after 770 SARS-CoV-2 challenge four days p.i. (n=12 per treatment group) relative to non-treated non-infected 771 controls (n=4) (scale represents fold-change over controls). RNA levels were determined by RT-qPCR 772 on lung extracts, normalized for β-actin mRNA levels and fold-changes over the median of uninfected 773 controls were calculated using the 2 (-ΔΔCq) method. (F) Individual expression profiles of mRNA levels 774 of IL-6, IP-10, IFN-λ and MX2, with data presented as median ± IQR relative to the median of non-775 treated non-infected controls. For IFN-λ, where all control animals had undetectable RNA levels

T-cell responses were analyzed by ELISpot and intracellular cytokine staining (ICS) of splenocytes 802 isolated from ifnar -/mice 21 days post-prime (i.e., two weeks post-boost) immunization with YF-S1/2 803 (blue), YF-S0 (green), YF-S1 (red) in comparison to sham (white) or YF17D (grey). uncorrected Dunn's test (ns = Not-Significant, P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001). (G, H) 815Profiling of CD8 T-cells from YF-S1/2 and YF-S0 vaccinated mice by t-SNE analysis. t-distributed 816Stochastic Neighbor Embedding (t-SNE) analysis of spike-specific CD8 T-cells positive for at least one 817 intracellular marker (IFN-γ, TNF-α, IL-4) from splenocytes of ifnar -/mice immunized with YF-S1/2 or 818 YF-S0 (n=6 per group) after overnight stimulation with SARS-CoV-2 Spike peptide pool. Blue dots 819indicate IFN-γ expressing T-cells, red dots TNF-α expressing T-cells, and green dots IL-4 expressing 820CD8 T-cells. (H) Heatmap of IFN-γ expression density of spike-specific CD8 T-cells from YF-S1/2 821 and YF-S0 vaccinated mice. Scale bar represents IFN-γ expressing density (blue -low expression, red 822 -high expression) (see Figure S8 for full analysis). with SARS-CoV-2 after vaccination with YF-S0 in comparison to sham vaccinated animals, as 835 described for two-dose vaccination schedule (Figure 3 and Figure S5 ); log10-fold change relative to sham 836 vaccinated in viral RNA levels (D) and infectious virus loads (E) in the lung of vaccinated hamsters at 837 day four p.i. as determined by RT-qPCR and virus titration, respectively. Dotted line indicating lower 838limit of quantification (LLOQ) or lower limit of detection (LLOD) as indicated. Data shown are medians 839 ± IQR. Statistical significance between groups was calculated by the non-parametric ANOVA, Kruskall-840Wallis with uncorrected Dunn's test (ns = Non-Significant, P > 0.05, * P < 0.05, ** P < 0.01, **** P < 841 0.0001).